Agios Announces Exercise of Over-Allotment Option in Public Offering Read more about Agios Announces Exercise of Over-Allotment Option in Public Offering
Agios Announces Closing of Public Offering Read more about Agios Announces Closing of Public Offering
Agios Announces Pricing of $250 Million Public Offering of Common Stock Read more about Agios Announces Pricing of $250 Million Public Offering of Common Stock
Agios Announces Proposed Offering of Common Stock Read more about Agios Announces Proposed Offering of Common Stock
Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017 Read more about Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017
Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene Read more about Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation Read more about FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation
Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 Read more about Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones Read more about Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017 Read more about Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017